News

19

Nov, 2020

European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV

Tags: ,

On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision was based, in part, on data from the ODYSSEY trial. These small tablets can now be used in combination with other medicines for treating children living with HIV who are aged at least four weeks and weigh at least 3kg. CHMP’s positive opinion also supported the updated dosing recommendations for dolutegravir film-coated […]

READ MORE

19

Nov, 2020

#WorldAntimicrobialAwarenessWeek: Antimicrobial Stewardship Programs (ASPs)

Tags:

In the spirit of World Antimicrobial Awareness Week, we’d like to share a summary of the findings from the “Implementation and Impact of Paediatric Antimicrobial Stewardship Programs: A Systematic Scoping Review” study. As you may already know, Antimicrobial Stewardship Programs (ASPs) are a set of coordinated interventions designed to improve the selection of the appropriate agent, dose, route of administration, and therapy duration without compromising patient outcomes.

READ MORE

10

Nov, 2020

Louise Hill Presents NeoVanc Sub-study Results at ESPID 2020

Tags: ,

Louise Hill presented the findings of a NeoVanc sub-study at ESPID’s 2020 Virtual Meeting in late October. Below is a summary of the study and findings. Enterococcus (a bacterium) and candida (a fungus) can sometimes be found on or in the human body.  Occasionally enterococci can develop resistance to one of the antibiotics usually used to treat it – vancomycin. Vancomycin use has been linked to a rise in vancomycin-resistant enterococci and candida on or in the bodies of babies admitted to the neonatal intensive care unit. Babies with vancomycin-resistant […]

READ MORE

16

Oct, 2020

c4c publishes first peer reviewed publication

Tags:

The c4c project, co-coordinated by Penta together with Janssen, Bayer and the University of Liverpool, has had its first review, titled “European research networks to facilitate drug research in children”, published by the British Journal of Clinical Pharmacology.  We are proud to have the Penta_ID Network involved in such an impactful project as a speciality network.   This review discusses the need for a structured approach to drug development by establishing and utilizing research networks and infrastructure. The publication explores how research networks and infrastructure can address the unmet medical […]

READ MORE

16

Oct, 2020

Penta Projects in Schools: What do young people know about HIV?

 

Authors: Elena Mozzo; Valentina Ortolan; Elena Badio; Federica Batterman; and Chiara Novello In October 2019, Penta began hosting HIV educational sessions in 5 high schools in Padova, Italy. From October to December 2019, a total of 13 meetings were held with 16-year-old students. For each session, the first 2 hours consisted of a medical doctor discussing the scientific aspects of HIV infection, followed by 2 hours with an HIV activist, discussing the social aspects of HIV. Each student who attended the session was asked to complete an anonymous questionnaire before […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities